Griesinger G, Blockeel C, Kahler E, et al. - Via performing this systematic review and meta-analysis, researchers performed a comprehensive assessment of the evidence on the efficacy and safety of oral dydrogesterone vs micronized vaginal progesterone (MVP) for luteal phase support. Searching Embase and MEDLINE, they identified nine studies as eligible for inclusion; two studies had suitable IPD (full analysis sample: n = 1,957). In the meta-analysis of individual participant data (IPD), a significantly higher chance of ongoing pregnancy at 12 weeks of gestation and live birth was observed in correlation with oral dydrogesterone vs MVP. A statistically significant difference between oral dydrogesterone and MVP was observed in a meta-analysis combining IPD and aggregate data for all nine studies. The two groups had similar safety parameters. Altogether, this study suggests that a higher pregnancy rate and live birth rate may be obtained in women receiving oral dydrogesterone vs MVP for luteal phase support.